Real-World Lurbinectedin Exhibits Safety and Modest Efficacy in ES‑SCLC
Lurbinectedin (Zepzelca) demonstrates a favorable safety profile and modest efficacy as a compassionate‑use therapy in patients with extensive‑stage small cell lung cancer (ES‑SCLC).
Lurbinectedin (Zepzelca) displayed a favorable safety profile and modest efficacy outcomes as a therapy with compassionate use in patients with extensive-stage small cell lung cancer (ES‑SCLC), according to findings from a multicenter, international study published in the European Journal of Cancer.
These real‑world results support the use of lurbinectedin as a second‑line or later option for extensive‑stage small cell lung cancer, providing a chemotherapy‑free interval and a manageable toxicity profile, potentially improving patient quality of life.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Extensive-stage Small Cell Lung Cancer - Gallipoli Medical Research
- EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
- Treatment of Small‑Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
- Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.
- Cancer's protective shield: Blocking a signaling pathway could make small cell lung tumors visible to T cells